Collagen Solutions PLC Notice of AGM (1802A)

TIDMCOS

RNS Number : 1802A

Collagen Solutions PLC

25 September 2020

Collagen Solutions plc

("Collagen" or the "Company")

Notice of AGM

Collagen Solutions plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life , announces that it is today posting a circular (the "Circular") to shareholders containing the notice of Annual General Meeting ("AGM").

The AGM will be held at the Company's offices at 3 Robroyston Oval, Nova Business Park, Glasgow G33 1AP at 11.00 a.m. (UK time) on 23 October 2020, however, as a result of the current COVID-19 pandemic and the legislative measures and associated guidance introduced by the UK and Scottish Governments in response, for the safety of our Shareholders, our employees, our advisers and the general public, the AGM will be held as a closed meeting.

Attendance by Shareholders at the AGM in person will not be possible and Shareholders or their appointed proxies (other than the chairman of the AGM) will not be permitted entry to the AGM. Further information on the arrangements for the AGM are set out in the Circular.

In the light of these measures the Directors of the Company strongly encourage shareholders to vote by proxy on all of the matters of business by appointing the Chairman of the Meeting as their proxy by submitting a proxy appointment in accordance with the instructions in the Circular and the proxy form.

Offer by Rosen's Diversified, Inc

On 27 August 2020, the Boards of Directors of the Company and Rosen's Diversified, Inc ("RDI") announced that agreement had been reached on the terms of a recommended cash offer by RDI for the entire issued and to be issued share capital of the Company not already owned by RDI (the "Offer"). The offer document containing the full terms and conditions of the Offer and the related form of acceptance were published on 14 September 2020.

The AGM is being convened in view of the Company's obligations under the Companies Act 2006. Whether or not you have accepted or intend to accept the Offer, you are still entitled to vote at the AGM, provided that you remain on the register of members of the Company at the relevant time. Where you have accepted the Offer before the AGM, your vote at the AGM will still be counted if: (i) you have followed the instructions set out in the notice of AGM and (where applicable) the accompanying form of proxy; and (ii) you are registered in the register of members of the Company at close of trading on 21 October 2020 (or, in the event of any adjournment of the AGM, on the date which is two days before the time of the adjourned meeting). Changes to the register of members after the relevant deadline, whether as a result of acceptance of the Offer or otherwise, shall be disregarded in determining the rights of any person to vote at the meeting.

Annual report and accounts for the year ended 31 March 2020

On 31 July 2020, the Company announced its unaudited results for the year ended 31 March 2020. The Company had previously announced on 15 June 2020 that it had been granted an extension to the filing deadline for its audited consolidated accounts for the year ended 31 March 2020 to 31 December 2020 in light of the ongoing COVID-19 pandemic. Accordingly, the audited consolidated accounts for the year ended 31 March 2020 and the directors' reports thereon are not enclosed with the Circular and will not be laid before the AGM.

 
 Collagen Solutions Plc 
                                                                 Via Walbrook 
 Jamal Rushdy, CEO 
 Hilary Spence, CFO 
 
 Cenkos Securities Plc (Nominated 
  Adviser and Broker) 
 Giles Balleny (Corporate                                  Tel: [phone] 
  Finance) 
 Stephen Keys 
 
 Walbrook PR Ltd                Tel: [phone] or [e-mail] 
 Anna Dunphy                                               Mob: [phone] 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOAEAANSAEEEEFA

(END) Dow Jones Newswires

September 25, 2020 08:02 ET (12:02 GMT)